PARP Inhibitor–Based Combinations to Improve Patient Outcomes in Prostate Cancer: An Evidence-Based Global Perspective

In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the rationale for using PARP inhibitors in combination with other therapies for prostate cancer.

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 15, 2021

Download this slideset to learn more about the rationale for combining PARP inhibitors with a variety of agents including androgen receptor directed therapy, immune checkpoint inhibitors, and DNA damaging agents as discussed in our podcast.

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 16, 2021

In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the latest results from ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostatic cancer.

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021

Download this slideset to learn more about the clinical trials discussed in our podcast focused on PARP inhibitor combination approaches to broaden the utility of PARP inhibition in prostate cancer.

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021